E Pina1, M Antonio2, J Peris3, E Rosselló3, P Domènech3, J Peñafiel4,5, C Tebe4,6. 1. Thrombosis and Haemostasis Unit, Hospital Universitari de Bellvitge, IDIBELL (Institut D'Investigació Biomèdica de Bellvitge), University of Barcelona, Av Feixa Llarga, s/n 08907, L'Hospitalet de Llobregat, Barcelona, Spain. epina@bellvitgehospital.cat. 2. Medical Oncology Department, Institut D'Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català D'Oncologia (ICO)-Hospital Duran I Reynals, University of Barcelona, Barcelona, Spain. 3. Thrombosis and Haemostasis Unit, Hospital Universitari de Bellvitge, IDIBELL (Institut D'Investigació Biomèdica de Bellvitge), University of Barcelona, Av Feixa Llarga, s/n 08907, L'Hospitalet de Llobregat, Barcelona, Spain. 4. Biostatistics Unit, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. 5. Basic Clinical Practice Department, University of Barcelona, Barcelona, Spain. 6. Basic Clinical Practice Department, Rovira Virgili University, Reus, Spain.
Abstract
INTRODUCTION: Low-molecular-weight heparin (LMWH) is the standard treatment for cancer-associated venous thromboembolism (VTE). There have been no specific studies evaluating bemiparin for VTE in people with cancer. The aim of this study is to evaluate the effects of bemiparin for long-term treatment of VTE in routine clinical practice. METHODS/PATIENTS: Prospective observational study. Consecutive patients with active cancer and VTE, under treatment with bemiparin for at least 6 months, were recruited. RESULTS: We included 89 patients. The 6- and 9-month cumulative VTE recurrence rates were 2.4% and 5.9%, respectively. The 6-month cumulative rate of major bleeding was 1.3%, and of clinically relevant non-major bleeding, 8%. CONCLUSIONS: The incidence of events in this study is lower than that reported in randomized trials. Bemiparin is effective and safe for the long-term treatment of cancer-associated VTE in routine clinical practice.
INTRODUCTION: Low-molecular-weight heparin (LMWH) is the standard treatment for cancer-associated venous thromboembolism (VTE). There have been no specific studies evaluating bemiparin for VTE in people with cancer. The aim of this study is to evaluate the effects of bemiparin for long-term treatment of VTE in routine clinical practice. METHODS/PATIENTS: Prospective observational study. Consecutive patients with active cancer and VTE, under treatment with bemiparin for at least 6 months, were recruited. RESULTS: We included 89 patients. The 6- and 9-month cumulative VTE recurrence rates were 2.4% and 5.9%, respectively. The 6-month cumulative rate of major bleeding was 1.3%, and of clinically relevant non-major bleeding, 8%. CONCLUSIONS: The incidence of events in this study is lower than that reported in randomized trials. Bemiparin is effective and safe for the long-term treatment of cancer-associated VTE in routine clinical practice.
Authors: Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores Journal: Chest Date: 2016-01-07 Impact factor: 9.410
Authors: Steven R Deitcher; Craig M Kessler; Geno Merli; James R Rigas; Roger M Lyons; Jawed Fareed Journal: Clin Appl Thromb Hemost Date: 2006-10 Impact factor: 2.389
Authors: Agnes Y Y Lee; Pieter W Kamphuisen; Guy Meyer; Rupert Bauersachs; Mette S Janas; Mikala F Jarner; Alok A Khorana Journal: JAMA Date: 2015-08-18 Impact factor: 56.272
Authors: D Farge; P Debourdeau; M Beckers; C Baglin; R M Bauersachs; B Brenner; D Brilhante; A Falanga; G T Gerotzafias; N Haim; A K Kakkar; A A Khorana; R Lecumberri; M Mandala; M Marty; M Monreal; S A Mousa; S Noble; I Pabinger; P Prandoni; M H Prins; M H Qari; M B Streiff; K Syrigos; H Bounameaux; H R Büller Journal: J Thromb Haemost Date: 2013-01 Impact factor: 5.824
Authors: Gary E Raskob; Nick van Es; Peter Verhamme; Marc Carrier; Marcello Di Nisio; David Garcia; Michael A Grosso; Ajay K Kakkar; Michael J Kovacs; Michele F Mercuri; Guy Meyer; Annelise Segers; Minggao Shi; Tzu-Fei Wang; Erik Yeo; George Zhang; Jeffrey I Zwicker; Jeffrey I Weitz; Harry R Büller Journal: N Engl J Med Date: 2017-12-12 Impact factor: 91.245
Authors: Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine Journal: J Clin Oncol Date: 2018-05-10 Impact factor: 44.544